Vinorelbine combined with cisplatin in advanced stage non-small-cell lung cancer / 中国癌症杂志
China Oncology
;
(12)2001.
Article
in Chinese
| WPRIM
| ID: wpr-539455
ABSTRACT
Purpose:
To evaluate the efficacy and toxicity of vinorelbine combined with cisplatin (NP regimen) in the treatment of advanced non-small-cell lung cancer ( NSCLC).Methods:
ninety-one patients with advanced NSCLC were confirmed by pathology or cytology. There were 56 patients with lung adenocarcinoma, 27 with squamous carcinoma and 4 with alveoli cell cancer, 3 with large-cell lung cancer, one case diagnosed by cytological smear section. The eighty patients had no prior chemotherapy and 11 were those without received previously chemotherapy. Thirty-two patients had stage Ⅲ disease and 59 had stage Ⅳ.Results:
Partial response was observed in 37 patients with an overall response rate of 40. 7% (95%CI30. 5%-50. 7%). Median time to progression (TTP) were 5 months(95% CI 4-6 months). Median survival duration was 13 months (95% CI 11-15months), one-year survival rate was 52. 7% ( CI 42. 4%-62. 9%). The dose limiting toxicity was neutropenia that was observed in 87. 9% of the patients (40.7% in grades Ⅲ and Ⅳ). The remission response rate is 40. 6% , TTP is 5 months, MS is 13 months and 1-year survival rate was 52.7% .Conclusions:
The results indicate NP regimen for advanced NSCLC is promise, and the toxicities are tolerable.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
China Oncology
Year:
2001
Type:
Article
Similar
MEDLINE
...
LILACS
LIS